Cytomegalovirus viral load kinetics in patients with HIV/AIDS admitted to a medical intensive care unit : a case for pre-emptive therapy

Loading...
Thumbnail Image

Authors

Mayaphi, Simnikiwe Horatious
Brauer, Marieke
Morobadi, Daniel M.
Mazanderani, Ahmad Haeri
Mafuyeka, Rendani T.
Olorunju, Steve A.S.
Tintinger, Gregory Ronald
Stoltz, Anton Carel

Journal Title

Journal ISSN

Volume Title

Publisher

Public Library of Science

Abstract

BACKGROUND : Cytomegalovirus (CMV) infection is associated with severe diseases in immunosuppressed patients; however, there is a lack of data for pre-emptive therapy in patients with HIV/AIDS. METHOD : This was a retrospective study, which enrolled patients diagnosed with HIV/AIDS (CD4,200 cells/ml), who had detectable CMV viral load (VL) during their stay in an adult medical intensive care unit between 2009–2012. RESULTS : After screening 82 patients’ records, 41 patients met the enrolment criteria. Their median age was 37 (interquartile range [IQR]: 31–46), and median CD4 count was 29 cells/ml (IQR: 5–55). Sixteen patients (39%) had serial measurements of CMV VL before treatment with ganciclovir. Patients whose baseline CMV VL values were between 1,000–3,000 copies/ml had significantly higher values (median of 14,650 copies/ml) on follow-up testing done 4–12 days later. Those with undetectable VLs at baseline testing had detectable VLs (median of 1,590 copies/ml) mostly within 20 days of follow-up testing. Patients who had VLs .1,000 copies/ml at baseline testing had significantly higher mortality compared to those who had ,1,000 copies/ml {hazard ratio of 3.46, p = 0.003 [95% confidence interval (CI): 1.55–7.71]}. Analysis of the highest CMV VL per patient showed that patients who had VLs of .5,100 copies/ml and did not receive ganciclovir had 100% mortality compared to 58% mortality in those who received ganciclovir at VLs of .5,100 copies/ml, 50% mortality in those who were not treated and had low VLs of ,5,100 copies/ml, and 44% mortality in those who had ganciclovir treatment at VLs of ,5,100 copies/ml (p = 0.084, 0.046, 0.037, respectively). CONCLUSION : This study showed a significantly increased mortality in patients with HIV/AIDS who had high CMV VLs, and suggests that a threshold value of 1,000 copies/ml may be appropriate for pre-emptive treatment in this group.

Description

Keywords

Therapy, HIV/AIDS, Human immunodeficiency virus (HIV), Acquired immune deficiency syndrome (AIDS), Cytomegalovirus (CMV), CMV viral load (VL), Immunosuppressed patients

Sustainable Development Goals

Citation

Mayaphi SH, Brauer M, Morobadi DM, Mazanderani AH, Mafuyeka RT, et al. (2014) Cytomegalovirus Viral Load Kinetics in Patients with HIV/AIDS Admitted to a Medical Intensive Care Unit: A Case for Pre-Emptive Therapy. PLoS ONE 9(4): e93702. DOI:10.1371/journal.pone.0093702.